In this episode of Clinical Trialblazers, host Alberto Grignolo sits down with Reenie McCarthy, the CEO of Mighty Therapeutics, formerly known as Stealth BioTherapeutics. Reenie shares her path from venture investor to biotech CEO and the years-long effort to develop and secure approval for a first-in-class therapy targeting mitochondrial dysfunction. She discusses the scientific, regulatory, and funding challenges of advancing a novel treatment through clinical development, as well as the critical role of patient advocacy and the lessons learned from setbacks that ultimately helped shape the company's success. The conversation also explores the future of mitochondrial medicine and Mighty Therapeutics' mission to bring innovative treatments to patients with serious unmet needs.
In this episode of Clinical Trialblazers, host Alberto Grignolo sits down with Reenie McCarthy, the CEO of Mighty Therapeutics, formerly known as Stealth BioTherapeutics. Reenie shares her path from venture investor to biotech CEO and the years-long effort to develop and secure approval for a first-in-class therapy targeting mitochondrial dysfunction. She discusses the scientific, regulatory, and funding challenges of advancing a novel treatment through clinical development, as well as the critical role of patient advocacy and the lessons learned from setbacks that ultimately helped shape the company's success.
The conversation also explores the future of mitochondrial medicine and Mighty Therapeutics' mission to bring innovative treatments to patients with serious unmet needs.